NCT01109615

Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Phase II Study of Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Vejle Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to investigate the efficacy and safety of the combination of pemetrexed and gemcitabine in heavily pre-treated, chemotherapy resistant colorectal cancer patients with KRAS mutations.

Conditions

• Metastatic Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Pemetrexed	400 mg/m2 on day 1 of a 3 weeks cycle
DRUG	Gemcitabine	1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-08-01
• Completion: 2012-03-01
• First posted: 2010-04-23
• Last updated: 2012-04-19

Locations

1 site across 1 country: Denmark